CANDIDA ALBICANS SHTAMMLARINING ANTIFUNGAL REZISTENTLIGI VA PEDIATRIK DAVOLASH STRATEGIYALARI
Keywords:
Kalit so‘zlar: Candida albicans, antifungal rezistentlik, pediatriya, kandidoz infeksiyalari, biofilm, antifungal preparatlar, bolalarda davolash strategiyalari, azol rezistentligi.Abstract
So‘nggi yillarda Candida albicans qo‘ziqorin shtammlarining antifungal
preparatlarga nisbatan rezistentlik darajasining ortib borishi pediatrik amaliyotda
dolzarb muammolardan biriga aylanmoqda. Ayniqsa, immun tizimi to‘liq
shakllanmagan bolalarda kandidoz infeksiyalarining tez-tez uchrashi va davolash
jarayonida dorilarga javobning pasayishi klinik natijalarga salbiy ta’sir ko‘rsatmoqda.
Ushbu maqolada Candida albicans shtammlarida antifungal rezistentlikning
molekulyar va fenotipik mexanizmlari, jumladan biofilm hosil qilish qobiliyati, gen
ekspressiyasidagi o‘zgarishlar hamda azol va polien guruhidagi preparatlarga
moslashuv jarayonlari tahlil qilinadi. Shuningdek, pediatrik bemorlar uchun xavfsiz va
samarali davolash strategiyalarini ishlab chiqishda yoshga xos farmakokinetik
xususiyatlar, dori tanlashdagi cheklovlar hamda individual yondashuvning ahamiyati
yoritiladi. Tadqiqot natijalari antifungal rezistentlikni kamaytirishga qaratilgan
ratsional davolash rejalarini shakllantirish va pediatrik infeksion kasalliklar
amaliyotini takomillashtirishga xizmat qiladi.
References
FOYDALANILGAN ADABIYOTLAR RO‘YXATI
1. Calderone R.A., Clancy C.J. Candida and Candidiasis. 2nd ed. Washington DC:
ASM Press; 2012.
2. Pappas P.G., Lionakis M.S., Arendrup M.C., Ostrosky-Zeichner L., Kullberg
B.J. Invasive candidiasis. Nature Reviews Disease Primers. 2018;4:18026.
3. Perfect J.R. The antifungal pipeline: a reality check. Nature Reviews Drug
Discovery. 2017;16(9):603–616.
4. Cowen L.E., Sanglard D., Howard S.J., Rogers P.D., Perlin D.S. Mechanisms of
antifungal drug resistance. Cold Spring Harbor Perspectives in Medicine.
2015;5(7):a019752.
5. Whaley S.G., Berkow E.L., Rybak J.M., Nishimoto A.T., Barker K.S., Rogers
P.D. Azole antifungal resistance in Candida albicans. Frontiers in
Microbiology. 2017;7:2173.
6. Silva S., Rodrigues C.F., Araújo D., Rodrigues M.E., Henriques M. Candida
species biofilms’ antifungal resistance. Journal of Fungi. 2017;3(1):8.
7. Arendrup M.C., Patterson T.F. Multidrug-resistant Candida: epidemiology,
molecular mechanisms, and treatment. Journal of Infectious Diseases.
2017;216(S3):S445–S451.
8. Roilides E., Katragkou A., Walsh T.J. Antifungal agents and therapy in neonates
and children. Current Fungal Infection Reports. 2010;4(4):239–248.
9. Zaoutis T.E., Benjamin D.K., Steinbach W.J. Antifungal treatment in pediatric
patients. Clinical Infectious Diseases. 2005;40(9):1323–1334.
10. Kullberg B.J., Arendrup M.C. Invasive candidiasis. New England Journal of
Medicine. 2015;373(15):1445–1456.
11. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis. Clinical
Microbiology Reviews. 2007;20(1):133–163.
12. Walsh T.J., Dixon D.M. Deep mycoses: diagnosis and treatment. European
Journal of Clinical Microbiology & Infectious Diseases. 1989;8(11):971–
988.
